Teacher Retirement System of Texas Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Teacher Retirement System of Texas reduced its stake in shares of Kura Oncology, Inc. (NASDAQ:KURAFree Report) by 21.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,202 shares of the company’s stock after selling 3,288 shares during the period. Teacher Retirement System of Texas’ holdings in Kura Oncology were worth $175,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C boosted its position in Kura Oncology by 35.1% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after purchasing an additional 1,136,044 shares in the last quarter. Vanguard Group Inc. increased its position in Kura Oncology by 7.5% during the third quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock worth $35,791,000 after purchasing an additional 275,173 shares during the last quarter. Armistice Capital LLC increased its holdings in shares of Kura Oncology by 5.3% during the 3rd quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock worth $20,392,000 after buying an additional 112,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Kura Oncology by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 579,987 shares of the company’s stock valued at $8,340,000 after purchasing an additional 16,566 shares during the period. Finally, Algert Global LLC raised its holdings in Kura Oncology by 95.1% in the 3rd quarter. Algert Global LLC now owns 365,024 shares of the company’s stock valued at $3,329,000 after buying an additional 177,959 shares during the period.

Insider Transactions at Kura Oncology

In other news, insider Teresa Brophy Bair sold 2,615 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.

Kura Oncology Trading Up 1.1 %

Kura Oncology stock opened at $20.69 on Friday. Kura Oncology, Inc. has a 52-week low of $7.41 and a 52-week high of $24.17. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -9.53 and a beta of 0.89. The firm has a 50-day moving average price of $20.48 and a two-hundred day moving average price of $17.63.

Kura Oncology (NASDAQ:KURAGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the business posted ($0.50) earnings per share. Kura Oncology’s quarterly revenue was up .0% on a year-over-year basis. Sell-side analysts expect that Kura Oncology, Inc. will post -2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, May 14th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, May 3rd. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.94.

Get Our Latest Research Report on Kura Oncology

About Kura Oncology

(Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Read More

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURAFree Report).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.